Send a Tweet
Most Popular Choices
Poll Analyses
Share on Facebook 14 Share on Twitter Printer Friendly Page More Sharing
OpEdNews Op Eds    H3'ed 3/20/20

Banks Pressure Health Care Firms To Raise Prices On Critical Drugs, Medical Supplies For Coronaviris

By       (Page 1 of 3 pages) (View How Many People Read This)   No comments
Author 70289
Message Lee Fang
Become a Fan
  (4 fans)

From The Intercept

The coronavirus pandemic and the crisis of capitalism
The coronavirus pandemic and the crisis of capitalism
(Image by YouTube, Channel: In Defence of Marxism)
  Details   DMCA

IN RECENT WEEKS, investment bankers have pressed health care companies on the front lines of fighting the novel coronavirus, including drug firms developing experimental treatments and medical supply firms, to consider ways that they can profit from the crisis.

The media has mostly focused on individuals who have taken advantage of the market for now -- scarce medical and hygiene supplies to hoard masks and hand sanitizer and resell them at higher prices. But the largest voices in the health care industry stand to gain from billions of dollars in emergency spending on the pandemic, as do the bankers and investors who invest in health care companies.

Over the past few weeks, investment bankers have been candid on investor calls and during health care conferences about the opportunity to raise drug prices. In some cases, bankers received sharp rebukes from health care executives; in others, executives joked about using the attention on Covid-19 to dodge public pressure on the opioid crisis.

Gilead Sciences, the company producing remdesivir, the most promising drug to treat Covid-19 symptoms, is one such firm facing investor pressure.

Remdesivir is an antiviral that began development as a treatment for dengue, West Nile virus, and Zika, as well as MERS and SARS. The World Health Organization has said there is "only one drug right now that we think may have real efficacy in treating coronavirus symptoms" namely, remdesivir.

The drug, though developed in partnership with the University of Alabama through a grant from the federal government's National Institutes of Health, is patented by Gilead Sciences, a major pharmaceutical company based in California. The firm has faced sharp criticism in the past for its pricing practices. It previously charged $84,000 for a yearlong supply of its hepatitis C treatment, which was also developed with government research support. Remdesivir is estimated to produce a one-time revenue of $2.5 billion.

During an investor conference earlier this month, Phil Nadeau, managing director at investment bank Cowen & Co., quizzed Gilead Science executives over whether the firm had planned for a "commercial strategy for remdesivir" or could "create a business out of remdesivir."

Johanna Mercier, executive vice president of Gilead, noted that the company is currently donating products and "manufacturing at risk and increasing our capacity" to do its best to find a solution to the pandemic. The company at the moment is focused, she said, primarily on "patient access" and "government access" for remdesivir.

"Commercial opportunity," Mercier added, "might come if this becomes a seasonal disease or stockpiling comes into play, but that's much later down the line."

Steven Valiquette, a managing director at Barclays Investment Bank, last week peppered executives from Cardinal Health, a health care distributor of N95 masks, ventilators and pharmaceuticals, on whether the company would raise prices on a range of supplies.

Valiquette asked repeatedly about potential price increases on a variety of products. Could the company, he asked, "offset some of the risk of volume shortages" on the "pricing side"?

Next Page  1  |  2  |  3

 

Rate It | View Ratings

Lee Fang Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

LEE FANG  Lee Fang is a  reporting fellow with The Investigative Fund at The Nation Institute. He covers money in politics, conservative movements and lobbying. Lee's work has resulted in multiple calls for hearings in Congress and the (more...)
 
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Romney Hires Voter Suppression Guru

GOP Mogul Behind Drug Rehab "Torture" Centers Is Bankrolling Opposition to Pot Legalization in Colorado

In Recorded Message To Drone Lobby Group, Congressman Rick Berg Brags About Loyalty To Industry

Revealed: Secretive Group Working To Suppress Voting In Maine Funded In Part By Wisconsin Businesses

Saudi-Led Oil Lobby Group Financed 2012 Dark Money Attack Ads

Grover Norquist's Budget Is Largely Financed by Just Two Billionaire-Backed Nonprofits

Comments Image Post Article Comment and Rate This Article

These discussions are not moderated. We rely on users to police themselves, and flag inappropriate comments and behavior. In accordance with our Guidelines and Policies, we reserve the right to remove any post at any time for any reason, and will restrict access of registered users who repeatedly violate our terms.

  • OpEdNews welcomes lively, CIVIL discourse. Personal attacks and/or hate speech are not tolerated and may result in banning.
  • Comments should relate to the content above. Irrelevant, off-topic comments are a distraction, and will be removed.
  • By submitting this comment, you agree to all OpEdNews rules, guidelines and policies.
          

Comment Here:   


You can enter 2000 characters. To remove limit, please click here.

Please login or register. Afterwards, your comment will be published.
 

Username
Password

Forgot your password? Click here and we will send an email to the address you used when you registered.
First Name
Last Name

I am at least 16 years of age
(make sure username & password are filled in. Note that username must be an email address.)

No comments  Post Comment

 
Want to post your own comment on this Article? Post Comment